The operating system for the AI-native biotech

Buying AI is easy. Becoming a different company is the hard part.

That hard part is the actual work, and it decides who gets medicine to patients first. I've spent a decade doing it inside real companies, and this is the playbook, every week.

AI-enabled versus AI-native On the left, an unchanged stack of the same work with an AI tool bolted on. On the right, the same work redesigned into a new, connected structure. AI-ENABLED AI the same company, faster AI-NATIVE a company redesigned
Why this matters

You can buy every model on the market and still be the same company next year. That failure never shows up as a line in a budget.

It shows up as a therapy that reaches a patient late, or never, because a company that could have moved faster did not.

This was never about efficiency. It is about who gets medicine to people first.

The capacity that closes that gap has a name.

Translational intelligence is the institutional capacity to convert emerging technological capability into durable scientific, operational, and strategic advantage.

Read the founding argument →
The path

You build it one piece at a time.

Here is the whole system, in the order it makes sense to learn it. Each piece has a name, and each one you can actually build.

  1. 1
    The idea

    Translational Intelligence

    The capacity to keep turning new capability into advantage, as fast as it arrives.

  2. 2
    The system

    Permission, People, Programs

    The operating system that builds that capacity, across three pillars that grow together.

  3. 3
    The discipline

    Buy the System of Record. Build the System of Intelligence.

    Where to spend and where not to, so your edge is the part only you can build.

  4. 4
    The role

    The AI Product Partner

    The person who carries it into the work and makes the change stick.

  5. 5
    The destination

    The AI-Native Biotech

    The company you become when it runs. It never stops translating.

Alexander Titus
Who's handing you this

I'm Titus. For a decade I've built AI into biotech from the inside. Pandemic response at Google. The genotype-to-phenotype engineering team at Colossal. Enterprise AI transformation at Avidity. The same charge now at Alloy, through Vigilance. And a Commissioner advising Congress on the future of emerging biotech. The rooms keep changing. The job never does: turn what these systems can now do into what an institution actually does, then do it again. I've run this play enough times to know exactly where it breaks and how to get it right, and I'm handing you all of it, every week, because translational intelligence leads to faster translational science for patients.

More about me →

No hype. No panic. No tool tourism.

Build the biotech of tomorrow.

Subscribe